AAO

Advanced imaging technologies like intraoperative OCT and heads-up displays enhance surgical precision and patient outcomes in retina surgery.

Stephen Tsang, MD, PhD, reviews promising optogenetic therapy results for retinitis pigmentosa and Stargardt disease, enhancing vision and mobility for patients.

A study reveals that cryopreserved amniotic membrane enhances recovery and reduces infection risk in post-corneal cross-linking patients.

Kenneth C. Fan, MD, discusses promising visual improvements from MCO-010 therapy for Stargardt disease at AAO 2025, highlighting future treatment potential.

Sharon Fekrat, MD, FACS, FASRS, shares insights on the retinal manifestations of antipsychotic medications.

Surgeons explore innovative cataract surgery techniques that significantly lower intraocular pressure while ensuring patient safety and comfort.

Anat Loewenstein, MD, discusses the transformative impact of home OCT and AI on monitoring retinal diseases at AAO 2025.

Discover the latest advancements in laser vision correction, including next-gen LASIK techniques that achieve unprecedented visual outcomes.

It seems there is no text provided for summarization. Please provide the text you'd like summarized, and I'll be happy to help!

Karolinne M. Rocha, MD, PhD, shares advancements in vision correction and patient satisfaction at the AAO 2025 meeting.

Johnson & Johnson reaches 100,000 TECNIS ODYSSEY IOLs implanted, and presented data on in vision correction and patient satisfaction at the AAO 2025 meeting.

Data suggests that EYP-1901 can reduce the number of injections and treatment burden for patients

Dr. James Chelnis explores innovative energy-based technologies in aesthetic facial surgery, emphasizing safety, personalized treatments, and future advancements in patient care.

The professor from Wills Eye Hospital in Philadelphia, Pennsylvania, explained why it's time to retire the term "sterile" when addressing culture-negative endophthalmitis

The AAO 2025 meeting offered a platform for companies to showcase their latest technologies to advance ophthalmic patient care.

Andrew G. Lee, MD, and Drew Carey, MD, discuss the case of a patient with persistent papilledema after brain tumor resection due to superficial siderosis.

A new study reveals a promising drug reduces vision loss in Stargardt disease, showing significant safety and efficacy over 2 years.

The awards recognize outstanding contributions in 3 categories—Rising Star, Catalyst, and Visionary Leader—honoring individuals driving innovation, inclusion, and impact across ophthalmology.

Catch up on news you may have missed at the meeting in Orlando, like the effects of GLP-1 drugs on eye health and a potential sign of cardiovascular disease.

Anat Loewenstein, MD, shared recent research findings which indicate home monitoring is appropriate for atypical and complex pathologies

HELIOS Phase 1 showed consistent reductions in retinal fluid with OTX-TKI, paving the way for pivotal HELIOS-2 and HELIOS-3 trials.

Gildeuretinol has also been evaluated in atrophic age-related macular degeneration, said Philip J. Ferrone, MD

The newest research findings create "tangible benchmarks" for how earlier treatment can lead to better outcomes, said Dr. Kim.

New research reveals subretinal drusenoid deposits in Black and Hispanic AMD patients may signal higher vascular disease risk

Optogenetics shows promise in improving mobility and object recognition for patients with retinitis pigmentosa and Stargardt disease.